Bavarian Nordic’s Big Rally Just the Latest in Volatile History
- Stock is on track for steepest monthly gain since July 2022
- Shares of the vaccine maker have seen spikes both ways
This article is for subscribers only.
This month’s near 50% rally in Bavarian Nordic A/S shares is nothing unusual for the Danish vaccine developer. But then again, neither are the falls that have often followed.
The stock is on track for its biggest monthly advance since July 2022 following a lethal outbreak of mpox in Africa, with Bavarian Nordic one of just a few companies having an approved vaccine. But even with this month’s gains, the stock is trading roughly 30% below its 2022 peak.